Scientists discuss the rationale for the combinational use and summarized the current data on the combinations of BTK inhibitors and venetoclax in patients with chronic lymphocytic leukemia and mantle cell lymphoma.
[Biomarker Research]
Sorry, but the selected Zotpress account can't be found.
